Pfizer Inc (PFE) News $PFE
Better Buy: Pfizer vs. CONSOL Energy
David Williamson and Taylor Muckerman, The Motley Fool - Motley Fool - 8 mins ago
In today's second-round match-up of The Motley Fool's Better-Buy Tournament, Pfizer squares off against CONSOL Energy in a battle to determine which stock is the better buy now. The 64-company tournament pits two Motley Fool analysts against each...
Most active New York Stock Exchange-traded stocks
AP - Fri Mar 21, 5:03PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Fri Mar 21, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
The Pfizer Drama That Wasn't
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 21, 2:39PM CDT
Trading in Pfizer was stopped last week for pending news. That's not something you see every day. Small biotechs, on the other hand, often get halted for big news. MannKind will likely be halted for most of April 1 as the Food and Drug...
3 Upcoming FDA Meetings You Should be Watching
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 21, 1:05PM CDT
Just because we're out of earnings season doesn't mean there aren't big data-driven events happening in the health care sector. Between now and the end of the month there are three Food and Drug Administration panel meetings that are bound to...
Midday Glance: Pharmaceuticals companies
AP - Fri Mar 21, 12:24PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Fri Mar 21, 9:46AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Next Resistance Level for Pfizer (PFE) is $32.32
Comtex SmarTrend(R) - Fri Mar 21, 9:02AM CDT
Shares of Pfizer (NYSE
FE) opened today above their pivot of $31.91 and have already reached the first level of resistance at $32.12. Should the shares continue to rise, the resistance pivots of $32.32 and $32.73 will be of interest.
Can These Companies Bounce Back from Disappointing Sales?
Dan Carroll, The Motley Fool - Motley Fool - Fri Mar 21, 8:30AM CDT
Bristol-Myers Squibb and Pfizer have rallied back from the patent cliff as well as any companies in big pharma, and both these standout firms have looked toward the future in igniting investor optimism. But one drug captured all the hype around...
Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Magellan Health Services Inc. (NASDAQ: MGLN), Prothena Corporation plc (NASDAQ: PRTA), Alere Inc. (NYSE: ALR), and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Ranking Big Pharma's Top Drugs of 2013
Max Macaluso, The Motley Fool - Motley Fool - Thu Mar 20, 5:30PM CDT
In 2012, AbbVie 's Humira brought in $9.3 billion in total sales and was the best selling drug in the world. But did the autoimmune disease drug, which accounts for more than half of AbbVie's sales, keep its crown in 2013? In the following...
Do You Take Statins? If Not, You May Be Soon
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 20, 4:03PM CDT
If you're over the age of 45 and are at risk of heart disease, your doctor may start recommending you take statins like Pfizer 's Lipitor, Merck's Zetia, or AstraZeneca 's Crestor. Those drugs are part of a class of cholesterol fighting...
Better Buy: Cubist Pharmaceuticals, Inc. vs. Durata Therapeutics, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 20, 8:30AM CDT
Regulatory decisions are generally chaotic events for biotech companies, especially when they involve a lead clinical candidate. Approvals can send shares soaring as the market prices in future revenue, whereas a rejection nearly always results in a...
Pfizer's Investigational Vaccine Candidate Bivalent rLP2086 Receives U.S. Food and Drug Administration Breakthrough Therapy Designation for Potential Prevention of Meningococcal B Disease
Business Wire - Thu Mar 20, 7:31AM CDT
Pfizer Inc. (NYSE FE) announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Pfizer's vaccine candidate, bivalent rLP2086, currently under investigation for the prevention of invasive meningococcal disease due to Neisseria meningitidis serogroup B in persons 10 - 25 years of age. Disease caused by Neisseria meningitidis serogroup B has been estimated at between 20,000 and 80,000 cases per year globally, and can result in death or significant long-term disabilities, including brain damage and hearing loss.(1,2)
Healthcare Companies Report FDA Approvals, Comprehensive Analysis, Schedules, and Stock Movements - Analyst Notes on Pfizer, Johnson & Johnson, Biogen, Express Scripts, and Forest Laboratories
PR Newswire - Thu Mar 20, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ), Biogen Idec Inc. (NASDAQ: BIIB), Express Scripts Inc. (NASDAQ: ESRX), and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Better Buy: Pfizer vs. CONSOL Energy
David Williamson and Taylor Muckerman, The Motley Fool - Motley Fool - 8 mins ago
In today's second-round match-up of The Motley Fool's Better-Buy Tournament, Pfizer squares off against CONSOL Energy in a battle to determine which stock is the better buy now. The 64-company tournament pits two Motley Fool analysts against each...
Most active New York Stock Exchange-traded stocks
AP - Fri Mar 21, 5:03PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Fri Mar 21, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
The Pfizer Drama That Wasn't
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 21, 2:39PM CDT
Trading in Pfizer was stopped last week for pending news. That's not something you see every day. Small biotechs, on the other hand, often get halted for big news. MannKind will likely be halted for most of April 1 as the Food and Drug...
3 Upcoming FDA Meetings You Should be Watching
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 21, 1:05PM CDT
Just because we're out of earnings season doesn't mean there aren't big data-driven events happening in the health care sector. Between now and the end of the month there are three Food and Drug Administration panel meetings that are bound to...
Midday Glance: Pharmaceuticals companies
AP - Fri Mar 21, 12:24PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Fri Mar 21, 9:46AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Next Resistance Level for Pfizer (PFE) is $32.32
Comtex SmarTrend(R) - Fri Mar 21, 9:02AM CDT
Shares of Pfizer (NYSE
FE) opened today above their pivot of $31.91 and have already reached the first level of resistance at $32.12. Should the shares continue to rise, the resistance pivots of $32.32 and $32.73 will be of interest. Can These Companies Bounce Back from Disappointing Sales?
Dan Carroll, The Motley Fool - Motley Fool - Fri Mar 21, 8:30AM CDT
Bristol-Myers Squibb and Pfizer have rallied back from the patent cliff as well as any companies in big pharma, and both these standout firms have looked toward the future in igniting investor optimism. But one drug captured all the hype around...
Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Magellan Health Services Inc. (NASDAQ: MGLN), Prothena Corporation plc (NASDAQ: PRTA), Alere Inc. (NYSE: ALR), and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Ranking Big Pharma's Top Drugs of 2013
Max Macaluso, The Motley Fool - Motley Fool - Thu Mar 20, 5:30PM CDT
In 2012, AbbVie 's Humira brought in $9.3 billion in total sales and was the best selling drug in the world. But did the autoimmune disease drug, which accounts for more than half of AbbVie's sales, keep its crown in 2013? In the following...
Do You Take Statins? If Not, You May Be Soon
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 20, 4:03PM CDT
If you're over the age of 45 and are at risk of heart disease, your doctor may start recommending you take statins like Pfizer 's Lipitor, Merck's Zetia, or AstraZeneca 's Crestor. Those drugs are part of a class of cholesterol fighting...
Better Buy: Cubist Pharmaceuticals, Inc. vs. Durata Therapeutics, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 20, 8:30AM CDT
Regulatory decisions are generally chaotic events for biotech companies, especially when they involve a lead clinical candidate. Approvals can send shares soaring as the market prices in future revenue, whereas a rejection nearly always results in a...
Pfizer's Investigational Vaccine Candidate Bivalent rLP2086 Receives U.S. Food and Drug Administration Breakthrough Therapy Designation for Potential Prevention of Meningococcal B Disease
Business Wire - Thu Mar 20, 7:31AM CDT
Pfizer Inc. (NYSE
FE) announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Pfizer's vaccine candidate, bivalent rLP2086, currently under investigation for the prevention of invasive meningococcal disease due to Neisseria meningitidis serogroup B in persons 10 - 25 years of age. Disease caused by Neisseria meningitidis serogroup B has been estimated at between 20,000 and 80,000 cases per year globally, and can result in death or significant long-term disabilities, including brain damage and hearing loss.(1,2) Healthcare Companies Report FDA Approvals, Comprehensive Analysis, Schedules, and Stock Movements - Analyst Notes on Pfizer, Johnson & Johnson, Biogen, Express Scripts, and Forest Laboratories
PR Newswire - Thu Mar 20, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ), Biogen Idec Inc. (NASDAQ: BIIB), Express Scripts Inc. (NASDAQ: ESRX), and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
